- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Di | Oppenheimer initiates Aardvark Therapeutics stock with Outperform rating | 2 | Investing.com | ||
| AARDVARK THERAPEUTICS Aktie jetzt für 0€ handeln | |||||
| Di | Oppenheimer startet Coverage für Aardvark Therapeutics mit "Outperform" | 1 | Investing.com Deutsch | ||
| 12.12. | William Blair initiates coverage on Aardvark Therapeutics stock with Outperform rating | 1 | Investing.com | ||
| 12.12. | William Blair nimmt Coverage für Aardvark Therapeutics mit "Outperform" auf | 4 | Investing.com Deutsch | ||
| 11.12. | Aardvark Therapeutics stock rises 13% on positive trial updates, BTIG maintains Buy | 1 | Investing.com | ||
| 11.12. | Raymond James bestätigt Aardvark Therapeutics mit "Strong Buy" und Kursziel von 47 $ | 3 | Investing.com Deutsch | ||
| 11.12. | Raymond James reiterates Strong Buy on Aardvark Therapeutics stock with $47 target | 4 | Investing.com | ||
| 10.12. | Aardvark Therapeutics, Inc.: Aardvark Therapeutics Announces First Patient Dosed in Australia in HERO Phase 3 Trial for Prader-Willi Syndrome | 117 | GlobeNewswire (Europe) | Multiple active sites and strong US enrollment continue to support Q3 2026 timing for topline data readout Clinical trial sites in Canada and the United Kingdom have received regulatory clearance... ► Artikel lesen | |
| 10.12. | Aardvark Therapeutics, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 02.12. | Raymond James startet Coverage für Aardvark Therapeutics mit "Strong Buy" und hohem Kurspotenzial | 5 | Investing.com Deutsch | ||
| 02.12. | Raymond James initiates coverage on Aardvark Therapeutics stock with Strong Buy | 3 | Investing.com | ||
| 14.11. | Stifel reiterates Buy rating on Aardvark Therapeutics stock, maintains $24 target | 1 | Investing.com | ||
| 14.11. | Aardvark Therapeutics stock price target lowered to $18 at RBC Capital | 1 | Investing.com | ||
| 13.11. | Aardvark Therapeutics, Inc.: Aardvark Therapeutics Reports Third Quarter 2025 Financial Results and Provides Pipeline and Business Updates | 256 | GlobeNewswire (Europe) | Aardvark has aligned with the FDA to reduce the minimum age of eligibility from 13 to 10 years old for pediatric patients in HERO, the Phase 3 trial of ARD-101 for the treatment of hyperphagia associated... ► Artikel lesen | |
| 13.11. | Aardvark Therapeutics, Inc. - 10-Q, Quarterly Report | - | SEC Filings | ||
| 13.11. | Aardvark Therapeutics, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 11.11. | Aardvark Therapeutics, Inc.: Aardvark Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(C)(4) | 3 | GlobeNewswire (USA) | ||
| 07.11. | BTIG stuft Aardvark Therapeutics mit "Buy" ein und sieht deutliches Kurspotenzial | 2 | Investing.com Deutsch | ||
| 07.11. | BTIG initiates coverage on Aardvark Therapeutics stock with Buy rating | 1 | Investing.com | ||
| 04.11. | Aardvark Therapeutics, Inc. - 8-K, Current Report | - | SEC Filings |
1 2 Weiter >>
40 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| MICROBOT MEDICAL | 1,740 | -5,69 % | Microbot Medical Inc.: Microbot Medical Receives First Patent in Japan as it Continues to Broaden its Global Intellectual Property Portfolio | Commercial Focus Remains on U.S. Market as it Continues to Explore Certain Global Markets that Accept FDA Cleared Devices Protecting its Innovative Technology Remains a Priority and Momentum Increasing... ► Artikel lesen | |
| VOYAGER THERAPEUTICS | 3,408 | +1,07 % | Voyager Therapeutics, Inc.: Voyager Reports Third Quarter 2025 Financial and Operating Results | - Momentum building around tau: expect VY7523 clinical data and VY1706 clinical entry in 2026 - - Sharpened focus on multi-modality pipeline with introduction of Voyager NeuroShuttle discovery... ► Artikel lesen | |
| CAPRICOR | 25,300 | +3,27 % | Capricor +727%: Biotech-Tipp schlägt heftig ein! | Capricor Therapeutics macht heute nicht nur mit positiven Studiennews auf sich aufmerksam: Dank eines gigantischen Multibagger-Kursfeuerwerks sorgt mein Biotech-Tipp aus dem Juli für glückselige Follower.... ► Artikel lesen | |
| ONCOLYTICS BIOTECH | 0,905 | -4,97 % | Oncolytics Biotech Inc.: Oncolytics Biotech Reports Updated Anal Cancer Data Showing Objective Response Rate More Than Double the Current Standard of Care | Pelareorep plus atezolizumab achieves 30% ORR in second-line or later (=2L) squamous cell anal carcinoma (SCAC) relative to 13.8% for the FDA-approved 2L treatment... ► Artikel lesen | |
| ABEONA THERAPEUTICS | 4,640 | +3,11 % | Abeona Therapeutics Inc.: Abeona Therapeutics Announces Appointment of Mohamad Tabrizi as Chief Business Officer | CLEVELAND, Dec. 15, 2025 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced the appointment of Mohamad Tabrizi, M.S., M.B.A., as Senior Vice President, Chief Business Officer... ► Artikel lesen | |
| DBV TECHNOLOGIES | 3,335 | +4,55 % | DBV Technologies S.A.: DBV Technologies Announces Positive Topline Results from Phase 3 VITESSE Trial of VIASKIN Peanut Patch in Peanut Allergic Children Aged 4-7 Years | Châtillon, France, December 16, 2025
DBV Technologies Announces Positive Topline Results from Phase 3 VITESSE Trial of VIASKIN Peanut Patch in Peanut Allergic Children Aged 4-7 Years
VITESSE... ► Artikel lesen | |
| PALVELLA THERAPEUTICS | 90,00 | +5,26 % | Palvella Therapeutics Inc.: Palvella Therapeutics Granted FDA Fast Track Designation for QTORIN 3.9% Rapamycin Anhydrous Gel (QTORIN rapamycin) for the Treatment of Angiokeratomas | Fast Track designation designed to facilitate the development, and expedite the review, of drugs to treat serious conditions and fill an unmet need With Fast Track designation, QTORIN rapamycin for... ► Artikel lesen | |
| ADICET BIO | 0,412 | +0,88 % | XFRA ISIN CHANGE | Einstellung Aufnahme ISIN Name Einstellung mit Ablauf: ISIN Name Ab dem: AnmerkungenAU0000111395 European Resources Ltd. 29.12.2025 AU0000448102 European Resources Ltd. 30.12.2025 Tausch 1:1US0070021086 Adicet... ► Artikel lesen | |
| MARKER THERAPEUTICS | 1,070 | +0,94 % | Marker Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Updates | APOLLO study showed encouraging overall responses and favorable safety profile in relapsed/refractory B-cell lymphoma MT-601 demonstrated 66% objective response rate with 50% complete response in... ► Artikel lesen | |
| KALVISTA PHARMACEUTICALS | 13,100 | -2,24 % | KalVista Pharmaceuticals, Inc.: KalVista Pharmaceuticals Announces Approval of EKTERLY (sebetralstat) in Japan, First and Only Oral On-demand Treatment for Hereditary Angioedema | KalVista Pharmaceuticals, Inc. (Nasdaq: KALV) today announced that the Ministry of Health, Labor and Welfare (MHLW) in Japan has granted marketing and manufacturing approval for EKTERLY (sebetralstat)... ► Artikel lesen | |
| CARTESIAN THERAPEUTICS | 5,350 | -0,93 % | Cartesian Therapeutics, Inc.: Cartesian Therapeutics Announces New Employment Inducement Grant | FREDERICK, Md., Oct. 03, 2025 (GLOBE NEWSWIRE) -- Cartesian Therapeutics, Inc. (NASDAQ: RNAC) (the "Company"), a clinical-stage biotechnology company pioneering cell therapy for autoimmune diseases... ► Artikel lesen | |
| QUANTUM-SI | 1,185 | -3,66 % | Quantum-Si stock rating reiterated by H.C. Wainwright on Proteus potential | ||
| PROTARA THERAPEUTICS | 4,800 | +5,26 % | Protara Therapeutics, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | NEW YORK, Oct. 01, 2025 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA) ("Protara" or the "Company"), a clinical-stage company developing transformative therapies for the treatment of... ► Artikel lesen | |
| SAGIMET BIOSCIENCES | 5,050 | -0,98 % | Sagimet Biosciences Inc.: Sagimet Biosciences Announces Positive Results from the Phase 1 PK Clinical Trial of Denifanstat and Resmetirom Combination | The combination of denifanstat and resmetirom was generally well-toleratedPharmacokinetic (PK) results support further development of the combinationA Phase 2 trial of a denifanstat/resmetirom combination... ► Artikel lesen | |
| CRINETICS PHARMACEUTICALS | 40,200 | -2,43 % | Crinetics Pharmaceuticals, Inc.: Crinetics Announces First Patient Dosed in Pivotal Adult Trial of Atumelnant in Congenital Adrenal Hyperplasia (CAH) | Phase 3 study builds on positive phase 2 results showing rapid and sustained reductions in key disease biomarkers and clinical measures of CAHSAN DIEGO, Dec. 11, 2025(Nasdaq: CRNX) today announced that... ► Artikel lesen |
Das Unternehmen AARDVARK THERAPEUTICS INC kann der Branche Biotechnologie zugeordnet werden. Die relative Kursveränderung beträgt aktuell +1,39 % bei einem Aktienkurs von 13,860 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu AARDVARK THERAPEUTICS INC finden Sie auf Wallstreet Online.